IL-25 treatment of obesity and metabolic disorders
The present invention provides a method for reducing the weight of a subject, preventing weight gain in a subject, lowering blood glucose, or treating hepatic steatosis, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising interleukin-25 or IL-25-activated macrophages. In addition, the present invention provides a method of treating cachexia or promoting weight gain in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising an inhibitor or antagonist of interleukin-25 in a mammal in the treatment of cachexia.
1. A method for reducing the weight of an obese subject thereby improving glucose metabolism and glucose homeostasis, in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising interleukin-25.
2. The method of claim 1 , wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable carriers.
3. The method of claim 2 , wherein the one or more pharmaceutically acceptable carriers is/are one or more liquid or solid fillers, diluents, excipients, solvents or encapsulating materials selected from the group consisting of: sugars, optionally lactose, glucose and/or sucrose; starches, optionally corn starch and/or potato starch; cellulose, and its derivatives, optionally sodium carboxymethyl cellulose, ethyl cellulose and/or cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, optionally cocoa butter and/or suppository waxes; oils, optionally peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and/or soybean oil; glycols, optionally propylene glycol; polyols, optionally glycerin, sorbitol, mannitol and/or polyethylene glycol; esters, optionally ethyl oleate and/or ethyl laurate; agar; buffering agents, optionally magnesium hydroxide and/or aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; and phosphate buffer solutions.
4. The method of claim 1 , wherein said composition administered to the subject in an amount of from about 0.5 mg/kg/day to about 1 mg/kg/day.
5. The method according to claim 1 , wherein the subject is a human, a cat or a dog.
6. The method according to claim 5 , wherein said human has a body mass index of at least about 25 kg/m 2 .
7. The method according to claim 1 , wherein said composition increases activation of macrophages in epididymal fat and liver.